转化医学

订阅

MedSci主页 / 所有栏目 / 转化医学

MicroRNA 与细胞信号通路的相互作用

2014-01-03 李 斌,郭燕华,徐辉,周惠,屈良鹄 生物化学与生物物理学进展

miRNA细胞信号通路调控
关注

 MicroRNA(miRNA)，广泛存在于多种生物中，在基因表达调控的转录后水平上发挥着重要的调节作 用．细胞信号通路转导外界刺激进而引发一系列生理和病理效应，决定着细胞的功能和命运．而miRNA和细胞信号通路间的相互作用对于二者的功能发挥起着关 键作用，本文将从信号通路对miRNA的调控和miRNA对信号通路的调节两方面综述二者的相互作用，揭示整合miRNA的细胞信号通路及其生物

 MicroRNA(miRNA)，广泛存在于多种生物中，在基因表达调控的转录后水平上发挥着重要的调节作 用．细胞信号通路转导外界刺激进而引发一系列生理和病理效应，决定着细胞的功能和命运．而miRNA和细胞信号通路间的相互作用对于二者的功能发挥起着关 键作用，本文将从信号通路对miRNA的调控和miRNA对信号通路的调节两方面综述二者的相互作用，揭示整合miRNA的细胞信号通路及其生物学意义．MicroRNA 与细胞信号通路的相互作用.pdf

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1857312, encodeId=014c185e312b1, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Jan 27 06:50:00 CST 2014, time=2014-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909170, encodeId=655c19091e0d8, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sat Nov 15 12:50:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084093, encodeId=d7ad20840932c, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Jun 24 16:50:00 CST 2014, time=2014-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435657, encodeId=9d88143565e08, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471493, encodeId=a2d314e149306, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539574, encodeId=557d15395e41b, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=)]
    2014-01-27 jiafufeng@yaho

    #CRO#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1857312, encodeId=014c185e312b1, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Jan 27 06:50:00 CST 2014, time=2014-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909170, encodeId=655c19091e0d8, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sat Nov 15 12:50:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084093, encodeId=d7ad20840932c, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Jun 24 16:50:00 CST 2014, time=2014-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435657, encodeId=9d88143565e08, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471493, encodeId=a2d314e149306, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539574, encodeId=557d15395e41b, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=)]
    2014-11-15 medscijoin

    #相互作用#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1857312, encodeId=014c185e312b1, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Jan 27 06:50:00 CST 2014, time=2014-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909170, encodeId=655c19091e0d8, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sat Nov 15 12:50:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084093, encodeId=d7ad20840932c, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Jun 24 16:50:00 CST 2014, time=2014-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435657, encodeId=9d88143565e08, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471493, encodeId=a2d314e149306, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539574, encodeId=557d15395e41b, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=)]
    2014-06-24 hb2008ye

    #Micro#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1857312, encodeId=014c185e312b1, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Jan 27 06:50:00 CST 2014, time=2014-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909170, encodeId=655c19091e0d8, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sat Nov 15 12:50:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084093, encodeId=d7ad20840932c, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Jun 24 16:50:00 CST 2014, time=2014-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435657, encodeId=9d88143565e08, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471493, encodeId=a2d314e149306, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539574, encodeId=557d15395e41b, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=)]
    2014-01-05 zhouqu_8

    #microRNA#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1857312, encodeId=014c185e312b1, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Jan 27 06:50:00 CST 2014, time=2014-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909170, encodeId=655c19091e0d8, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sat Nov 15 12:50:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084093, encodeId=d7ad20840932c, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Jun 24 16:50:00 CST 2014, time=2014-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435657, encodeId=9d88143565e08, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471493, encodeId=a2d314e149306, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539574, encodeId=557d15395e41b, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=)]
    2014-01-05 ylz8405

    #互作#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1857312, encodeId=014c185e312b1, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Mon Jan 27 06:50:00 CST 2014, time=2014-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909170, encodeId=655c19091e0d8, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f73a255, createdName=medscijoin, createdTime=Sat Nov 15 12:50:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2084093, encodeId=d7ad20840932c, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Jun 24 16:50:00 CST 2014, time=2014-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1435657, encodeId=9d88143565e08, content=<a href='/topic/show?id=31df11e1642' target=_blank style='color:#2F92EE;'>#microRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11716, encryptionId=31df11e1642, topicName=microRNA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471493, encodeId=a2d314e149306, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539574, encodeId=557d15395e41b, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sun Jan 05 12:50:00 CST 2014, time=2014-01-05, status=1, ipAttribution=)]
    2014-01-05 wgx310

    #信号通路#

    0

相关资讯

J Infect Dis：血浆病毒miRNA或可作为慢性活动型EB病毒感染分子标志

慢性活动型EB病毒感染（CAEBV）的临床特点类似于慢性或重复的感染性单核细胞增多症，如发热、淋巴结肿大等。CAEBV具有很高的发病率和死亡率，并伴随多种危及生命的并发症。造血干细胞移植已成为有效的治疗方法。血样本中的EB病毒DNA含量已被用于诊断疾病和评估疗效，但是，还没有发现能反映疾病严重程度、病程以及预后的其他生物标志物。miRNA属于小分子非编码RNA，与信使RNA的序列互补。已有研究表明

AJHG：有益脂肪或许能靶向miRNA降低心脏病风险

美国塔夫茨大学美国农业部人类营养老化研究中心(HNRCA)的科学家们已经发现了一个调节甘油三酸酯水平的新基因机制.这一途径可以保护一个基因变异的携带者对抗心血管疾病，特别是那些对多不饱和脂肪(PUFA)有更大摄入量的基因变异携带者.这一发现发表在 American Journal of Human Genetics杂志上，研究结果有助于开展能够改善公众健康和补充慢性疾病预防和治疗的基因特异的饮食策

缺乏两种小核糖核酸会导致不孕

当代社会不孕症发病率有明显上升趋势，而无法顺利排卵是导致不孕症的重要原因之一。日本一个研究小组在动物实验中发现，如果缺乏两种特定的小核糖核酸(miRNA)，会引发排卵障碍。 小核糖核酸是一类不编码制造蛋白质的单链核糖核酸分子，主要参与控制基因表达，调节各种基因的功能。研究小组在实验中发现，如果雌性实验鼠体内缺乏miR―200b和miR―429这两种小核糖核酸，就难以怀孕。 研究小组检查体内缺乏

JBC：中国医学科学院解析抑癌miRNA

来自中国医学科学院的研究人员在新研究中证实，miRNA-200b通过影响Pin1的表达控制了失巢凋亡（anoikis），且miRNA-200b的表达受到两个ETS家族成员PEA3和ELK-1的调控。这些研究发现在线发表在9月26日的《生物化学杂志》（JBC）上   【原文下载】 论文的通讯作者是中国医学科学院北京协和医学院的刘志华（Zhihua Liu）博士。其回国前曾在美国

Genome Biol：乳腺癌中DNA甲基化和拷贝数改变调控miRNA异常表达

   挪威奥斯陆大学等机构的研究人员对乳腺癌队列人群进行分析，揭示了DNA甲基化和拷贝数改变对microRNA表达的影响，从而为乳腺癌中miRNA失调背后的机制提供了新证据。这项研究成果于11月20日发表在Genome Biology上。 　　microRNA（miRNA）是一类小的非编码RNA分子，它通过控制mRNA稳定性和翻译而在转录后水平上调控基因表达。之前的研究

JBC：邬振国教授解析横纹肌肉瘤抑癌miRNA

来自深圳北京大学香港科技大学医学中心、香港科技大学的研究人员证实，在横纹肌肉瘤中miR-203常常下调，其再表达可以抑制横纹肌肉瘤的生长和转移，促进其终末分化，表明miR-203是横纹肌肉瘤一个有潜力的治疗靶点。相关论文发表在11月18日的《生物化学杂志》（JBC）上。 【原文下载】 文章的通讯作者是任职于深圳北京大学香港科技大学医学中心和香港科技大学的邬振